<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        18-370-05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SIMVATEN 40MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SIMVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        89.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 389]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Arabian Japanese Pharmaceutical Co. Ltd.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SIMVATEN&reg; is a medicine used to lower levels of total cholesterol, &ldquo;bad&quot; cholesterol (LDL cholesterol), and fatty substances called triglycerides in the blood, in addition, SIMVATEN&reg; raises levels of &ldquo;good&quot; cholesterol (HDL cholesterol). You should stay on a cholesterol-lowering diet while taking this medicine. SIMVATEN&reg; is a member of the class of drugs called statins.</p><p><strong>SIMVATEN&reg; is used when other measures such as exercise &amp; weight loss have failed</strong></p><p>SIMVATEN&reg; is used along with diet if you have:</p><p>&bull;A raised cholesterol level in your blood (primary hypercholesterolaemia) or elevated fat levels in your blood (mixed hyperlipidaemia)</p><p>&bull;A hereditary illness (homozygous familial hypercholesterolaemia) that increases the cholesterol level in your blood. You may also receive other treatments,</p><p>&bull;Coronary heart disease (CHD) or are at high risk of CHD (because you have diabetes، history of stroke، or other blood vessel disease). SIMVATEN&reg; may prolong your life by reducing the risk of heart disease problems, regardless of the amount of cholesterol in your blood,</p><p>In most people, there are no immediate symptoms of high cholesterol. Your doctor can measure your cholesterol with a simple blood test, Visit your doctor regularly, keep track of your cholesterol, and discuss your goals with your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take SIMVATEN&reg;</p><p>&bull;If you are allergic (hypersensitive) to simvastatin or any of the other ingredients of SIMVATEN&reg; Tablets</p><p>&nbsp;(see Section 6: Further Information(.</p><p>&bull;if you currently have liver problems</p><p>&bull;if you are pregnant or breast-feeding</p><p>&bull;if you are taking one or more than one of the following drugs at the same time:</p><p>-<strong>Itraconazole, Ketoconazole, or Posaconazole</strong> (medicines for fungal infections)</p><p>-<strong>Erythromycin, Clarithromycin, or Telithromycin</strong> (antibiotics for infections)</p><p>-<strong>Indinavir, Nelfinavir, Ritonavir, boceprevir, telaprevir and Saquinavir</strong> (HIV protease inhibitors are</p><p>used for HIV infections(</p><p>-<strong>Nefazodone</strong> (a medicine for depression)</p><p>-<strong>Gemfibrozil</strong> (a medicine for lowering cholesterol)</p><p>-<strong>Ciclosporin</strong> (a medicine often used in organ transplant patients)</p><p>-<strong>Danazol</strong> (a man-made hormone used to treat endometriosis).</p><p>Ask your doctor if you are not sure if your medicine is listed above.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Take special care with SIMVATEN&reg;</strong></p><p>-Tell your doctor about all your medical conditions including allergies.</p><p>-Tell your doctor if you drink large amounts of alcohol.</p><p>-Tell your doctor if you have ever had liver disease SIMVATEN&reg; may not be right for you.</p><p>-Tell your doctor if you are due to have an operation. You may need to stop taking SIMVATEN&reg; tablets for a short time.</p><p>-Your doctor should do a blood test before you start taking SIMVATEN&reg;. This is to check how well your liver is working,</p><p>-Tell your doctor if you have severe lung disease.</p><p>-Liver function tests should be performed prior to and at 12 week following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter, Liver enzyme changes generally occur in the first 3months of treatment with SIMVATEN&reg;</p><p>-Increase in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors including SIMVATEN&reg;</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Contact your doctor immediately if you experience unexplained muscle pain, tenderness, or weakness. This is because on rare occasions, muscle problems can be serious, including muscle breakdown resulting in kidney damage; and very rare deaths have occurred.</strong></p><p>The risk of muscle breakdown is greater at higher doses of SIMVATEN&reg;, particularly the 80 mg dose. The risk of muscle breakdown is also greater in certain patients. Talk with your doctor if any of the following applies:</p><p>-you consume large amounts of alcohol</p><p>-you have kidney problems</p><p>-you have thyroid problems</p><p>-you are 65 years or older</p><p>-you are female</p><p>-you have ever had muscle problems during treatment with cholesterol-lowering medicines called &ldquo;statins&quot; or fibrates</p><p>-You or a close family member have a hereditary muscle disorder.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Using other medicines</strong></p><p>It is particularly important to tell your doctor if you are taking any of the following drugs. Taking SIMVATEN&reg; with any of these drugs can increase the risk of muscle problems (some of these have already been listed in the above section &ldquo;Do not take SIMVATEN&quot;&reg;).</p><p><strong>Ciclosporin</strong> (a medicine often used in organ transplant patients)</p><p><strong>Danazol</strong> (a man-made hormone used to treat endometriosis) <strong>Itraconazole, Ketoconazole, Fluconazole, or Posaconazole</strong> (medicines for fungal infections)</p><p><strong>Fibrates like Gemfibrozil and Bezafibrate</strong> (medicines for lowering cholesterol)</p><p><strong>Erythromycin, Clarithromycin, Telithromycin, or Fusidic acid</strong> (medicines for bacterial infections) Indinavir, <strong>nelfinavir, ritonavir, and saquinavir</strong> (HIV protease inhibitors are used for HIV infections) Nefazodone (a medicine for depression)</p><p><strong>Amiodarone</strong> (a medicine for an irregular heartbeat)</p><p>In patients taking amiodarone, the dose of Simvastatin should not exceed 10 mg/day.</p><p><strong>Verapamil, Diltiazem, or Amlodipine</strong> (medicines for high blood pressure, chest pain associated with heart disease, or other heart conditions (</p><p><strong>Colchicine</strong> (a medicine used to treat gout (.</p><p>As well as the medicines listed above, tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those obtained without a prescription. In particular, tell your doctor if you are taking any of the following:</p><p><strong>Warfarin, Phenprocoumon or Acenocoumarol</strong> (anticoagulants)</p><p><strong>Fenoflbrate</strong> (another medicine for lowering cholesterol)</p><p><strong>Niacin</strong> (another medicine for lowering cholesterol).</p><p><strong>Rlfamplcln</strong> (a medicine used to treat tuberculosis).</p><p>Also, tell your doctor if Chinese are taking niacin (nicotinic acid) or a niacin-containing product</p><p>You should also tell any doctor who is prescribing a new medicine for you that you are taking SIMVATEN&reg;.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Taking SIMVATEN&reg; with food and drink</strong></p><p>Grapefruit juice contains one or more components that alter how the body uses some medicinal products, including SIMVATEN&reg;. Consuming grapefruit juice should be avoided.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pregnancy and Breast-feeding</strong></p><p>Do not take SIMVATEN&reg; if you are pregnant, trying to get pregnant or think you may be pregnant. If you get pregnant while taking SIMVATEN&reg;, stop taking it immediately and contact your doctor. Do not take SIMVATEN&reg; if you are breast-feeding, because it is not known if the medicine is passed into breast milk. Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Children</strong></p><p>Safety and effectiveness have been studied in 10-17 year old boys and in girls who had started their menstrual period at least one year before (see HOW TO TAKE SIMVATEN&reg;). SIMVATEN&reg; has not been studied in children under the age of 10 years.</p><p>Ask your doctor For more information</p><p><strong>Driving and using machines</strong></p><p>SIMVATEN&reg; is not expected to interfere with your ability to drive or to use machinery. However, it should be taken into account that some people get dizzy after taking SIMVATEN&reg;.</p><p>Important information about some of the ingredients of SIMVATEN&reg;</p><p>SIMVATEN&reg; tablets contain a sugar called lactose. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-Always take SIMVATEN&reg; exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>-You should stay on a cholesterol-lowering diet while taking SIMVATEN&reg;.</p><p>-Your doctor will determine the appropriate tablet strength for you، depending on your condition, your current treatment and your personal risk status.</p><p>-Take SIMVATEN&reg; in the evening.</p><p>-You can take it with or without food,</p><p>-Always swallow the tablets with plenty of water.</p><p>-The usual starting dose is 10, 20 or, in some cases, 40 mg a day. Your doctor may adjust your dose after at least 4 weeks to a maximum of 80 mg a day, Do not take more than 80 mg a day, Your doctor may prescribe lower doses, particularly if you are taking certain medicinal products listed above or have certain kidney conditions,</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The usual doses are:</strong></p><p>Adults:</p><p><strong>People with coronary heart disease (CHD)</strong></p><p>20 to 40mg a day, taken in the evening. The maximum dose is 80mg a day.</p><p>People with high levels of blood fats (Hyperlipidaemia)</p><p>The starting dose is 10 mg a day, taken in the evening. The maximum dose is 80mg a day.</p><p>The 80mg dose is only recommended for adult patients with very high cholesterol levels and at high risk of heart disease problems.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>People with inherited high cholesterol levels (Homozygous familial hypercholesterolaemia)</strong></p><p>40 mg a day, taken in the evening. The doctor may ask you to take a higher dose of 80 mg each day, taken in three doses through the day (20 mg, 20 mg and a 40 mg dose taken in the evening).</p><p>&nbsp;<u>Children</u>:</p><p>For children (10-17 years old), the recommended usual starting dose is 10mg a day in the evening. The maximum recommended dose is 40mg a day</p><p>Your doctor may ask you to take a lower dose, particularly if you are taking <strong>Ciclosporin, Danazol</strong>, <strong>other Fibrates or niacin</strong>, or if you have kidney problems,</p><p><strong>Taking another medicine for lowering your cholesterol at the same time as SIMVATEN&reg;</strong></p><p>&nbsp;Your doctor may ask you to take another medicine for lowering your cholesterol at the same time as taking SIMVATEN&reg;. This includes medicines such as cholestyramine (a resin-type medicine),</p><p>This type of medicine can change the way SIMVATEN&reg; works. You should take SIMVATEN&reg; at least two hours before or at least four hours after taking a resin-type medicine.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you take more SIMVATEN&reg; than you should</strong></p><p>If you take more SIMVATEN&reg; than you should, tell your doctor or go to your nearest hospital straight away. Take the carton and any SIMVATEN&reg; tablets left with you so that the doctors know what you have taken.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you forget to take SIMVATEN&reg;</strong></p><p>If you forget to take a dose, take it as soon as you remember, unless it is time for your next dose; do not take a double dose.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you stop taking SIMVATEN&reg;</strong></p><p>Continue taking SIMVATEN&reg;, unless your doctor tells you to stop. Your blood cholesterol levels may rise again once you stop taking SIMVATEN&reg;.</p><p><strong>If you have any further questions on the use of this product, ask your doctor or your pharmacist. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, SIMVATEN&reg; can cause side effects, although not everybody gets them.</p><p>The following terms are used to describe how often side effects have been reported:</p><p>&bull;Rare (occurring in 1 or more of 10,000 and less than 1 of 1000 patients treated (</p><p>&bull;Very rare (occurring in less than 1 of 10,000 patients treat. (</p><p>&bull;Frequency not known</p><p>Stop taking SIMVATEN&reg; and see a doctor or go to a hospital straight away if:</p><p>-You experience symptoms of angioedema, such as swollen face, tongue or throat, difficulty in breathing and swallowing and hives</p><p>-You get unexplained pain, tenderness or weakness in the muscles or pain in your joints, high temperature or tiredness</p><p>-You get a lumpy rash or flushing of the skin</p><p>-You get liver problems, such as yellowing of the skin or eyes (jaundice/hepatitis)</p><p>The following rare serious side effects were reported.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rare side effects (affects less than 1 in 100 people(</strong></p><p>Stomach pain, Constipation, Wind (flatulence), Diarrhoea Feeling sick or being sick (nausea or vomiting)</p><p>Weakness, Headache, Dizziness Skin rash or itching, Pins and needles Hair loss</p><p>Indigestion or severe abdominal pain (possibly caused by an inflamed pancreas)</p><p>Feeling breathless and very tired, this could mean you have low levels of red blood cells (anaemia) Muscle cramps, unexplained pain, tenderness or weakness in the muscles</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Frequency not known</strong></p><p>The following side effects have also been reported but the frequency cannot be estimated from the available information:</p><p>Erectile dysfunction , Depression .Inflammation of the lungs causing breathing problems including persistent cough and/or shortness of breath or fever .Tendon problems, sometimes complicated by rupture of the tendon.</p><p><strong>Very rare</strong> fatal and non-fatal hepatic failure</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Additional possible side effects reported with some statins:</strong></p><p>Sleep disturbances including nightmares, Memory loss .Sexual difficulties.</p><p>There have been rare post marketing reports of cognitive impairment (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) the reports are generally non-serious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Laboratory Values</strong></p><p>Elevations in some laboratory blood tests of liver function and a muscle enzyme (creatine kinase) have been observed.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not be alarmed by this list, most people take SIMVATEN&reg; without any problems.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Store below 30&deg;C.</p><p>Do not use SIMVATEN&reg; after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;The active substance is Simvastatin,</p><p>&bull;The other ingredients are: Lactose, Butylate Hydroxy Anisole, Hydroxypropylcellulose, Magnesium stearate, Opadry Pink.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                -SIMVATEN® 10 mg is Round, Pink, biconvex film coated tablet, Coded by SJ 115 on one side and plain on the other side. Packs of 30 tablets
-SIMVATEN® 20 mg is Round, Pink, biconvex film coated tablet, Coded by SJ 131 on one side and plain on the other side . Packs of 30 tablets
-SIMVATEN® 40 mg is Round, Pink, biconvex film coated tablet, Coded by SJ 123 on one side and plain on the other side. Packs of 30 tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals</p><p>Saudi Arabian Japanese pharmaceutical company limited Jeddah - Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jan/2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="direction: rtl;">سمفاتن هو دواء يُستخدم لخفض مستويات الكوليسترول الكلي والكوليسترول الضار (كوليسترول البروتين الدهني منخفض الكثافة &quot;LDL&quot;) والمواد الدهنية التي تعرف بـ&quot;الدهون الثلاثية&quot; الموجودة في الدم. بالإضافة إلى ذلك، يزيد سمفاتن من مستويات الكوليسترول &quot;المفيد&quot; (كوليسترول البروتين الدهني عالي الكثافة &quot;HDL&quot;). يجب عليك اتباع نظام غذائي خافض للكوليسترول أثناء تناول هذا الدواء. ينتمي سمفاتن إلى مجموعة الأدوية التي تعرف بالـ&quot;ستاتينات&quot;.</p><p style="direction: rtl;">يستخدم سمفاتن &nbsp;عند فشل الممارسات الرياضية وفقدان الوزن</p><p style="direction: rtl;">يُستخدَم سمفاتن &nbsp;إلى جانب النظام الغذائي في الحالات التالية:</p><p style="direction: rtl;">∙ ارتفاع مستوى الكوليسترول في الدم (فرط كوليسترول الدم &quot;الأولي&quot;)، أو ارتفاع مستويات الدهون في الدم (فرط دهون الدم من النوع &quot;المختلط&quot;).</p><p style="direction: rtl;">∙ مرض وراثي (فرط كوليسترول الدم العائلي متجانس الجينات) الذي يزيد من مستوى الكولسترول في الدم. قد تتلقى أيضًا علاجات أخرى.</p><p style="direction: rtl;">∙ أمراض القلب التاجية أو كانت لديك مخاطر مرتفعة للإصابة بأمراض الشرايين التاجية؛ (لأنك تعاني من مرض السكري، تاريخ مرضي للإصابة بسكتة دماغية، أو غيرها من أمراض الأوعية الدموية). قد يطيل سمفاتن عمرك عن طريق الحد من خطر التعرض لمشاكل أمراض القلب، بغض النظر عن كمية الكوليسترول في الدم.</p><p style="direction: rtl;">في معظم الأشخاص، لا تظهر أية أعراض فورية نتيجةً لارتفاع الكوليسترول في الدم، يمكن لطبيبك قياس الكوليسترول لديك من خلال فحص بسيط بالدم.</p><p style="direction: rtl;">قم بزيارة الطبيب الخاص بك بانتظام، وداوم على متابعة الكوليسترول لديك، ومناقشة أهدافك العلاجية مع الطبيب الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">لا تتناول سمفاتن في الحالات الآتية:</p><p style="direction: rtl;">∙ إذا كنت تعاني من حساسية (فرط الحساسية) تجاه &quot;سمفاستاتين&quot; أو أيّ من المكونات الأخرى (انظر قسم 6: &quot;معلومات إضافية&quot;).</p><p style="direction: rtl;">∙ إذا كنت حاليًا تعاني من مشاكل في الكبد.</p><p style="direction: rtl;">∙ إذا كنتِ حاملاً أو مرضعًا.</p><p style="direction: rtl;">∙ إذا كنت تتناول واحدًا أو أكثر من الأدوية التالية في نفس الوقت:</p><p style="direction: rtl;">- إيتراكونازول، كيتوكونازول، أو بوساكونازول (أدوية لعلاج العدوى الفطرية).</p><p style="direction: rtl;">- أريثروميسين، كلاريثروميسين، أو تيليثروميسين (مضادات حيوية لعلاج حالات العدوى).</p><p style="direction: rtl;">- أندينافير، نيلفينافير، ريتونافير، بوسيبريفير، تيلابريفير وساكوينافير (تُستخدم مثبطات إنزيم البروتياز الخاص بفيروس الإيدز لعلاج العدوى بفيروس نقص المناعة البشرية - الإيدز).</p><p style="direction: rtl;">- نيفازودون (دواء لعلاج الاكتئاب).</p><p style="direction: rtl;">- جيمفيبروزيل (دواء خافض للكوليسترول).</p><p style="direction: rtl;">- سيكلوسبورين (هو دواء يُستخدم في كثير من الأحيان في المرضى الذين خضعوا لعمليات زرع أعضاء).</p><p style="direction: rtl;">- دانازول (هرمون من صنع الإنسان يُستخدم لعلاج الانتباذ البطاني الرحمي - أي وجود نسيج بطانة الرحم بأماكن أخرى من الجسم إضافةً إلى مكانه الطبيعي بالرحم).</p><p style="direction: rtl;">استشر الطبيب الخاص بك إن لم تكن متأكدًا أن دواءك قد ورد بقائمة الأدوية المذكورة أعلاه.</p><p style="direction: rtl;">توخَ حذرًا خاصًا مع سمفاتن</p><p style="direction: rtl;">- أخبر طبيبك عن كل الحالات الطبية التي تعاني منها بما في ذلك الحساسية.</p><p style="direction: rtl;">- أخبر طبيبك إذا كنت تتناول كميات كبيرة من الكحوليات.</p><p style="direction: rtl;">- أخبر طبيبك إذا كنت قد أصبت بمرض كبدي من قبل، فقد يكون سمفاتن غير مناسب لك.</p><p style="direction: rtl;">- أخبر طبيبك إذا كنت بصدد الخضوع لعملية جراحية. فقد تحتاج إلى التوقف عن تناول سمفاتن لفترة قصيرة.</p><p style="direction: rtl;">- يجب على طبيبك إجراء اختبار الدم قبل البدء في تناول سمفاتن. وذلك للتحقق من أن الكبد يعمل بشكل جيد.</p><p style="direction: rtl;">- أخبر طبيبك إذا كنت تعاني من مرض رئوي شديد.</p><p style="direction: rtl;">- يجب أن يتم عمل اختبار وظائف الكبد قبل بدء العلاج بسمفاتن &nbsp;وبعد 12 أسبوع من بدء العلاج أو زيادة الجرعة، وبشكل دوري (على سبيل المثال، كل ستة أشهر) بعد ذلك. التغيير في انزيمات الكبد تحدث عمومًا في الثلاثة أشهر الأولى من بدء العلاج بسمفاتن .</p><p style="direction: rtl;">- قد يحدث زيادة في مستويات الجلوكوز في الدم ونسبة HbA1C مع سمفاتن .</p><p style="direction: rtl;">اتصل بطبيبك فورًا إذا واجهتك آلام، أو أوجاع، أو ضعف بالعضلات من غير مبرر؛ وذلك لأنه في حالات نادرة، يمكن لمشاكل العضلات أن تكون خطيرة، ويشمل ذلك تحلل العضلات الذي يؤدي إلى تلف الكلى، وقد حدثت حالات وفاة بصورة نادرة جدًا.</p><p style="direction: rtl;">∙ مخاطر تحلل العضلات تظهر بشكل أكبر في الجرعات المرتفعة من سمفاتن، وبخاصةً جرعة 80 ملج. تظهر أيضًا مخاطر تحلل العضلات بشكل أكبر في بعض المرضى، تحدث مع الطبيب الخاص بك إذا كان ينطبق عليك أيّ مما يلي:</p><p style="direction: rtl;">- تتناول كميات كبيرة من الكحوليات.</p><p style="direction: rtl;">- تعاني من مشاك في الكُلى.</p><p style="direction: rtl;">- تعاني من مشاكل في الغدة الدرقية.</p><p style="direction: rtl;">- تبلغ 65 عامًا أو أكثر.</p><p style="direction: rtl;">- إذا كنتِ أنثى.</p><p style="direction: rtl;">- سبق معاناتك من مشاكل في العضلات أثناء العلاج بالأدوية الخافضة للكوليسترول التي تعرف بالـ&quot;ستاتينات&quot;، أو الفايبرات.</p><p style="direction: rtl;">- لديك أنت أو أحد أفراد العائلة المقربين اضطراب وراثي في العضلات.</p><p style="direction: rtl;">استخدام أدوية أخرى:</p><p style="direction: rtl;">من الهام بصفة خاصة أن تخبر طبيبك إذا كنت تتناول أيًّا من الأدوية التالية، فتناول سمفاتن مع أيٍّ من هذه الأدوية قد يزيد من مخاطر الإصابة بمشاكل العضلات (بعضها قد تم بالفعل سرده في قسم &quot;لا تتناول سمفاتن&quot; أعلاه).</p><p style="direction: rtl;">- سيكلوسبورين (هو دواء يُستخدم عادةً في المرضى الذين قد خضعوا لجراحات زرع الأعضاء).</p><p style="direction: rtl;">- دانازول (هرمون من صنع الإنسان يُستخدم لعلاج انتباذ بطانة الرحم).</p><p style="direction: rtl;">- إيتراكونازول، كيتوكونازول، فلوكونازول، أو بوساكونازول (أدوية لعلاج العدوى الفطرية).</p><p style="direction: rtl;">- الفايبرات مثل جيمفيبروزيل وبيزافيبرات (أدوية خافضة للكولسترول).</p><p style="direction: rtl;">- أريثروميسين، كلاريثروميسين، تيليثروميسين أو حمض الفوسيديك (أدوية لعلاج العدوى البكتيرية).</p><p style="direction: rtl;">- أندينافير، نيلفينافير، ريتونافير، وساكوينافير (تُستخدم مثبطات إنزيم البروتياز الخاص بفيروس الإيدز لعلاج العدوى بفيروس نقص المناعة البشرية - الإيدز).</p><p style="direction: rtl;">- نيفازودون (دواء لعلاج الاكتئاب).</p><p style="direction: rtl;">- أميودارون (دواء لعلاج ضربات القلب غير المنتظمة).</p><p style="direction: rtl;">يجب ألا تتجاوز جرعة سمفاتن 10 ملج / يوم. في المرضى الذين يتناولون أميودارون.</p><p style="direction: rtl;">- فيراباميل، ديلتيازيم، أو أملوديبين (أدوية لعلاج ضغط الدم المرتفع، والآلام الصدرية المرتبطة بأمراض القلب، أو بعض حالات القلب الأخرى).</p><p style="direction: rtl;">- كولشيسين (وهو دواء يُستخدم لعلاج النقرس).</p><p style="direction: rtl;">فضلاً عن الأدوية المذكورة أعلاه، أخبر الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أية أدوية أخرى، بما فيها تلك التي تم الحصول عليها دون وصفة طبية. على وجه الخصوص، أخبر طبيبك إذا كنت تتناول أيًّا مما يلي:</p><p style="direction: rtl;">- وارفارين، ينبروكومون أو أسينوكومارول (مضادات التخثر).</p><p style="direction: rtl;">- فينوفيبرات (دواء آخر خافض للكوليسترول).</p><p style="direction: rtl;">- نياسين (دواء آخر خافض للكوليسترول).</p><p style="direction: rtl;">- ريفامبيسين (وهو دواء يُستخدم لعلاج مرض السل).</p><p style="direction: rtl;">أيضًا أخبر طبيبك أيضًا إذا كنت صينيًا وتتناول نياسين (حمض النيكوتينيك) أو أي منتج يحتوي على نياسين.</p><p style="direction: rtl;">يجب أيضًا أن تخبر أي طبيب يصف لك دواءً جديدًا أنك تتناول سمفاتن.</p><p style="direction: rtl;">تناول سمفاتن مع الطعام والشراب</p><p style="direction: rtl;">يحتوي عصير الجريب فروت على واحد أو أكثر من المكونات التي من شأنها أن تُغيّر الطريقة التي يستخدم بها الجسم بعض المنتجات الطبية؛ بما في ذلك سمفاتن. يجب تجنب تناول عصير الجريب فروت.</p><p style="direction: rtl;">الحمل والرضاعة الطبيعية</p><p style="direction: rtl;">لا تتناولي سمفاتن إذا كنت حاملاً، أو تنوين الحمل أو تظنين أنكِ قد تكونين حاملاً. إذا أصبحتِ حاملاً أثناء تناول سمفاتن، يجب وقف العلاج فورًا والاتصال بالطبيب الخاص بكِ. لا تتناولي سمفاتن إذا كنتِ مرضعًا، وذلك حيث إنه من غير المعروف ما إذا كان يتم مرور الدواء إلى لبن الأم.</p><p style="direction: rtl;">استشيري الطبيب الخاص بك أو الصيدلي قبل تناول أي دواء.</p><p style="direction: rtl;">الأطفال</p><p style="direction: rtl;">تمت دراسة أمان وفعالية سمفاتن في الفتيان من عمر 10 - 17 عامًا والفتيات اللاتي قد بدأت فترة الحيض لديهن (البلوغ) قبل سنة على الأقل (انظر القسم &quot;طريقة استخدام سمفاتن&quot;). لم تتم دراسة سمفاتن في الأطفال الذين تقل أعمارهم عن 10 أعوام.</p><p style="direction: rtl;">القيادة واستخدام الآلات</p><p style="direction: rtl;">من غير المتوقع أن يُؤثر سمفاتن في قدرتك على القيادة أو استخدام الآلات. ومع ذلك، ينبغي أن يُؤخذ في الاعتبار أن بعض الأشخاص قد أصيبوا بدوار بعد تناول سمفاتن.</p><p style="direction: rtl;">معلومات هامة عن بعض المكونات بـ سمفاتن:</p><p style="direction: rtl;">تحتوي أقراص سمفاتن على سكر الـ &quot;لاكتوز&quot;، إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاستشره قبل هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">- تناول دائمًا سمفاتن كما أخبرك طبيبك بالضبط. إذا لم تكن متأكدًا من كيفية التناول، يجب عليك مراجعة الطبيب أو الصيدلي الخاص بك.</p><p style="direction: rtl;">- يجب عليك اتباع نظام غذائي خافض للكوليسترول أثناء تناول سمفاتن.</p><p style="direction: rtl;">- سيحدد الطبيب الخاص بك تركيز الأقراص المناسبة لك، بناءً على حالتك، والعلاج الحالي الخاص بك ووضع المخاطر الشخصية بالنسبة لك.</p><p style="direction: rtl;">- تناول سمفاتن في المساء.</p><p style="direction: rtl;">- يمكنك تناوُل سمفاتن مع الطعام أو بدونه.</p><p style="direction: rtl;">- ابتلع الأقراص دائمًا مع الكثير من الماء.</p><p style="direction: rtl;">- جرعة البدء المعتادة هي 10 أو 20 أو في بعض الحالات 40 ملج يوميًا. قد يقوم طبيبك بضبط الجرعة بعد 4 أسابيع على الأقل لجرعة أقصاها 80 ملج في اليوم.</p><p style="direction: rtl;">لا تتناول أكثر من 80 ملج في اليوم. قد يصف طبيبك جرعات أقل وخاصة إذا كنت تتناول بعض المنتجات الدوائية المذكورة أعلاه أو تعاني من حالات معينة في الكُلى.</p><p style="direction: rtl;">الجرعات المعتادة هي:</p><p style="direction: rtl;">البالغون:</p><p style="direction: rtl;">الأشخاص الذين يعانون من أمراض القلب التاجية</p><p style="direction: rtl;">20 إلى 40 ملج في اليوم، يتم تناولها في المساء، الجرعة القصوى هي 80 ملج في اليوم.</p><p style="direction: rtl;">الأشخاص الذين يعانون من ارتفاع مستويات الدهون في الدم (فرط دهون الدم).</p><p style="direction: rtl;">جرعة البدء هي 10 ملج في اليوم، يتم تناولها في المساء. الجرعة القصوى هي 80 ملج في اليوم.</p><p style="direction: rtl;">يُوصى بجرعة 80 ملج فقط للمرضى البالغين الذين يعانون من مستويات مرتفعة جدًا من الكوليسترول ومعرضين لمخاطر مرتفعة من الإصابة بمشاكل أمراض القلب.</p><p style="direction: rtl;">الأشخاص الذين يعانون من ارتفاع وراثي بمستويات الكوليسترول (فرط كوليسترول الدم العائلي متجانس الجينات)</p><p style="direction: rtl;">40 ملج في اليوم، يتم تناولها في المساء. قد يطلب الطبيب منك تناول جرعة أعلى من 80 ملج يوميًا، يتم تناولها على ثلاث جرعات خلال اليوم (20 ملج، 20 ملج و40 ملج جرعة يتم تناولها في المساء).</p><p style="direction: rtl;"><u>الأطفال:</u></p><p style="direction: rtl;">للأطفال من عمر (10 - 17 سنة)، جرعة البدء المعتادة الموصى بها هي 10 ملج يوميًا في المساء، الجرعة القصوى الموصى بها هي 40 ملج في اليوم.</p><p style="direction: rtl;">قد يطلب الطبيب منك تناول جرعة أقل، خاصةً إذا كنت تتناول سيكلوسبورين، دانازول، أنواع أخرى من الفايبرات أو نياسين، أو إذا كنت تعاني من مشاكل في الكُلى.</p><p style="direction: rtl;">تناوُل دواء آخرًا لخفض نسبة الكوليسترول لديك في نفس الوقت الذي تتناول فيه سمفاتن: قد يطلب منك طبيبك أن تتناول دواءً آخر لخفض نسبة الكوليسترول في نفس الوقت الذي تتناول فيه سمفاتن. هذا يشمل الأدوية مثل الكوليسترامين (دواء من نوع الراتنج).</p><p style="direction: rtl;">ويمكن لهذا النوع من الدواء أن يغير من الطريقة التي يعمل بها سمفاتن. يجب أن تتناول سمفاتن قبل ساعتين على الأقل أو بعد أربع ساعات من تناول أي دواء من نوع الراتنج.</p><p style="direction: rtl;">إذا تناولت كمية من سمفاتن أكثر مما يجب</p><p style="direction: rtl;">إذا تناولت كمية من سمفاتن أكثر مما يجب، أخبر الطبيب الخاص بك، أو اذهب إلى أقرب مستشفى على الفور، خذ العبوة وأي أقراص متبقية من سمفاتن معك حتى يتسنى للأطباء معرفة ما تناولته.</p><p style="direction: rtl;">إذا نسيت أن تتناول سمفاتن</p><p style="direction: rtl;">إذا نسيت تناوُل إحدى الجرعات، فتناولها بمجرد تذكرك لها، إلا إذا كان قد حان موعد الجرعة التالية، لا تتناول جرعة مضاعفة.</p><p style="direction: rtl;">إذا توقفت عن تناول سمفاتن</p><p style="direction: rtl;">استمر في تناول سمفاتن، ما لم يخبرك طبيبك أن توقفه، قد ترتفع مستويات الكوليسترول في الدم مرة أخرى عند التوقف عن تناول سمفاتن.</p><p style="direction: rtl;">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">مثله مثل كافة الأدوية، قد يُسبب سمفاتن أعراضًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p style="direction: rtl;">تصف المصطلحات التالية معدل حدوث الأعراض الجانبية التي تم الإبلاغ عنها:</p><p style="direction: rtl;">∙ نادرة (تحدث في 1 أو أكثر من كل 10.000 مريض، ولكن أقل من 1 من كل 1.000 مريض تم علاجهم).</p><p style="direction: rtl;">∙ نادرة جدًا (تحدث في أقل من 1 من كل 10.000 مريض تم علاجهم).</p><p style="direction: rtl;">∙ نسبة الحدوث غير معروفة.</p><p style="direction: rtl;">توقف عن تناول سمفاتن، وقم بزيارة الطبيب، أو اذهب إلى المستشفى في الحال إذا:</p><p style="direction: rtl;">- واجهتك أعراض وذمة وعائية، مثل تورم اللسان والوجه أو الحلق، وصعوبة في التنفس والبلع، وشري (أرتكاريا).</p><p style="direction: rtl;">- أصبت بآلام، أو أوجاع، أو ضعف في العضلات غير مبرر أو آلام في المفاصل، أو ارتفاع في درجة الحرارة أو تعب.</p><p style="direction: rtl;">- أصبت بطفح جلدي عقدي (شري) أو احمراء في الجلد.</p><p style="direction: rtl;">- أصبت بمشاكل في الكبد، مثل اصفرار الجلد أو العينين (اليرقان / التهاب الكبد).</p><p style="direction: rtl;">تم الإبلاغ عن أعراض جانبية خطيرة نادرة الحدوث وهي كالتالي:</p><p style="direction: rtl;">أعراض جانبية نادرة (تُؤثر على أقل من 1 من 100 شخص)</p><p style="direction: rtl;">آلام في المعدة، وإمساك، ريح (انتفاخ البطن)، إسهال.</p><p style="direction: rtl;">الشعور بالإعياء أو الإعياء بالفعل (غثيان أو قيء).</p><p style="direction: rtl;">ضعف، صداع، ودوخة.</p><p style="direction: rtl;">طفح جلدي أو حكة، أو الإحساس كالوخز / كالإبر.</p><p style="direction: rtl;">تساقط الشعر.</p><p style="direction: rtl;">عسر الهضم أو آلام شديدة في البطن (ربما بسبب التهاب البنكرياس).</p><p style="direction: rtl;">الإحساس بانقطاع النفس والتعب الشديد، وقد يعني ذلك وجود مستويات منخفضة لديك من كريات الدم الحمراء (فقر الدم).</p><p style="direction: rtl;">تقلصات عضلية، وآلام، أو أوجاع، أو ضعف في العضلات من غير مبرر.</p><p style="direction: rtl;">أعراض جانبية نادرة جدًا:</p><p style="direction: rtl;">فشل كبدي</p><p style="direction: rtl;">نسبة الحدوث غير معروفة:</p><p style="direction: rtl;">تم الإبلاغ عن الأعراض الجانبية التالية، ولكن لا يمكن تقدير معدل تكرارها من واقع البيانات المتاحة</p><p style="direction: rtl;">خلل في الانتصاب، اكتئاب، التهاب في الرئتين يُسبب مشاكل في التنفس بما في ذلك السعال المستمر و / أو ضيق التنفس أو الحمى، مشاكل بالأوتار، قد تكون في بعض الأحيان مصحوبة بتمزق الوتر (مضاعفات).</p><p style="direction: rtl;">أشارت دراسات ما بعد التسويق حدوث حالات نادرة من ضعف الإدراك (مثل فقدان الذاكرة، والنسيان، ضعف الذاكرة، والارتباك) وهذه الأعراض عادة ما تكون غير خطيرة، ومرتجعة بعد التوقف عن تناول سمفاتن ، في مدة زمنية تتراوح من (1 يوم إلى سنة) منذ ظهور الأعراض وزوال الأعراض (3 أسابيع مدة زمنية متوسطة).</p><p style="direction: rtl;">تم الإبلاغ عن أعراض جانبية إضافية محتملة مع بعض الـ&quot;ستاتينات&quot;</p><p style="direction: rtl;">اضطرابات في النوم بما في ذلك الإصابة بكوابيس، فقدان الذاكرة، صعوبات جنسية.</p><p style="direction: rtl;">نتائج الفحوصات المعملية</p><p style="direction: rtl;">لوحظ ارتفاع في بعض فحوصات الدم المعملية الخاصة بوظائف الكبد وأحد الإنزيمات العضلية (إنزيم كيناز الكرياتين).</p><p style="direction: rtl;">إذا أصبح أيّ من الأعراض الجانبية خطيرًا، أو إذا لاحظت أية أعراض جانبية غير الواردة في هذه النشرة، فيُرجى إبلاغ الطبيب أو الصيدلي الخاص بك.</p><p style="direction: rtl;">لا تنزعج من قائمة الأعراض الجانبية، فمعظم الأشخاص يتناولون سمفاتن من دون أي مشاكل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ بعيدًا عن مُتناول ورؤية الأطفال.</p><p>- يُحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p>- لا تستخدم سمفاتن بعد تاريخ انتهاء الصلاحية المدون على العبوة، يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">- المادة الفعّالة هي سمفاستاتين.</p><p style="direction: rtl;">- المكونات الأخرى هي: لاكتوز، بوتيل هيدروكسي الأنيسول، هيدروكسي بروبيل السليلوز، ستيرات الماغنسيوم، أوبادري وردي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            - أقراص سمفاتن 10 ملج هي أقراص مغلفة، وردية اللون، محدبة الوجهين محفور عليها SJ 115  من أحد الوجهين، تحتوي العبوة على 30 قرصًا مغلفًا.
- أقراص سمفاتن 20 ملج هي أقراص مغلفة وردية اللون، محدبة الوجهين محفور عليها SJ 131  من أحد الوجهين، تحتوي العبوة على 30 قرصًا مغلفًا.
- أقراص سمفاتن 40 ملج هي أقراص مغلفة، وردية اللون، محدبة الوجهين محفور عليها SJ 123  من أحد الوجهين، تحتوي العبوة على 30 قرصًا مغلفًا.

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مصنع ساجا للصناعات الدوائية</p><p>الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة</p><p>جدة &ndash; المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير/ 2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SIMVATEN 10mg, 20mg and 40mg Film coated Tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 10 mg, 20 mg and 40mg of simvastatin.
Excipients: Lactose monohydrate
For full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
- SIMVATEN 10 mg is Round, Pink, biconvex film coated tablet, Coded by SJ
115 on one side.
- SIMVATEN 20 mg is Round, Pink, biconvex film coated tablet, Coded by SJ
131 on one side.
- SIMVATEN 40 mg is Round, Pink, biconvex film coated tablet, Coded by SJ
123 on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypercholesterolaemia<br />Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct<br />to diet, when response to diet and other non-pharmacological treatments (e.g.<br />exercise, weight reduction) is inadequate.<br />Treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and<br />other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are not<br />appropriate.<br />Cardiovascular prevention<br />Reduction of cardiovascular mortality and morbidity in patients with manifest<br />atherosclerotic cardiovascular disease or diabetes mellitus, with either normal or<br />increased cholesterol levels, as an adjunct to correction of other risk factors and<br />other cardioprotective therapy (see section 5.1).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dosage range is 5-80 mg/day given orally as a single dose in the evening.<br />Adjustments of dosage, if required, should be made at intervals of not less than 4<br />weeks, to a maximum of 80 mg/day given as a single dose in the evening. The 80-mg<br />dose is only recommended in patients with severe hypercholesterolaemia and high<br />risk for cardiovascular complications, who have not achieved their treatment goals<br />on lower doses and when the benefits are expected to outweigh the potential risks<br />(see section 4.4 and 5.1).<br />Hypercholesterolaemia<br />The patient should be placed on a standard cholesterol-lowering diet, and should<br />continue on this diet during treatment with Simvastatin. The usual starting dose is<br />10-20 mg/day given as a single dose in the evening. Patients who require a large<br />reduction in LDL-C (more than 45 %) may be started at 20-40 mg/day given as a<br />single dose in the evening. Adjustments of dosage, if required, should be made as<br />specified above.<br />Homozygous familial hypercholesterolaemia<br />Based on the results of a controlled clinical study, the recommended dosage is<br />Simvastatin 40 mg/day in the evening or 80 mg/day in 3 divided doses of 20 mg, 20<br />mg, and an evening dose of 40 mg. Simvastatin should be used as an adjunct to other<br />lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments<br />are unavailable.<br />Cardiovascular prevention<br />The usual dose of Simvastatin is 20 to 40 mg/day given as a single dose in the<br />evening in patients at high risk of coronary heart disease (CHD, with or without<br />hyperlipidaemia). Drug therapy can be initiated simultaneously with diet and<br />exercise. Adjustments of dosage, if required, should be made as specified above.<br />Concomitant therapy<br />Simvastatin is effective alone or in combination with bile acid sequestrants. Dosing<br />should occur either &gt; 2 hours before or&gt; 4 hours after administration of a bile acid<br />sequestrant. In patients taking ciclosporin, danazol, gemfibrozil or other fibrates<br />(except fenofibrate) concomitantly with Simvastatin, the dose of Simvastatin should<br />not exceed 10 mg/day. In patients taking amiodarone orverapamil concomitantly<br />with Simvastatin, the dose of Simvastatin should not exceed 20 mg/day. In patients<br />taking diltiazem or amtopidine concomitantly with Simvastatin, the dose of<br />Simvastatin should not exceed 40mg/day (See sections 4.4 and 4.5.)<br />Dosage in renal insufficiency<br />No modification of dosage should be necessary in patients with moderate renal<br />insufficiency. In patients with severe renal insufficiency (creatinine clearance &lt; 30<br />ml/min), dosages above 10 mg/day should be carefully considered and, if deemed<br />necessary, implemented cautiously.<br />Use in the elderly<br />No dosage adjustment is necessary.<br />Use in children and adolescents (10-17 years of age)<br />For children and adolescents (boys Tanner Stage II and above and girls who are at<br />least one year post-menarche, 10-17 years of age) with heterozygous familial<br />hypercholesterolaemia, the recommended usual starting dose is 10 mg once a day in<br />the evening. Children and adolescents should be placed on a standard cholesterollowering diet before simvastatin treatment initiation; this diet should be continued<br />during simvastatin treatment.<br />The recommended dosing range is 10-40 mg/day; the maximum recommended dose<br />is 40 mg/day. Doses should be individualized according to the recommended goal of<br />therapy as recommended by the paediatric treatment recommendations (see<br />sections 4.4 and 5.1). Adjustments should be made at intervals of 4 weeks or more.<br />The experience of simvastatin in pre-pubertal children is limited.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to simvastatin or to any of the excipients
Active liver disease or unexplained persistent elevations of serum transaminases.
Pregnancy and lactation (see section 4.6)
Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole,
ketoconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin,
clarithromycin, telithromycin and nefazodone) (see section 4.5).
Concomitant administration of gemfibrozil, cicliosporin, or dnazol (see section 4.4
and 4.5)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Myopathy/Rhabdomyolysis<br />Simvastatin, like other inhibitors of HMG-CoA reductase, occasionally causes<br />myopathy manifested as muscle pain, tenderness or weakness with creatine kinase<br />(CK) above ten times the upper limit of normal (ULN). Myopathy sometimes takes<br />the form of rhabdomyolysis with or without acute renal failure secondary to<br />myoglobinuria, and very rare fatalities have occurred. The risk of myopathy is<br />increased by high levels of HMG-CoA reductase inhibitory activity in plasma.<br />As with other HMG-CoA reductase inhibitors, the risk of myopathy/rhabdomyolysis is<br />dose related. In a clinical trial database in which 41,413 patients were treated with<br />Simvastatin 24,747 (approximately 60%) of whom were enrolled in studies with a<br />median follow-up of at least 4 years, the incidence of myopathy was approximately<br />0.03%, 0.08% and 0.61% at 20, 40 and 80 mg/day, respectively. In these trials,<br />patients were carefully monitored and some interacting medicinal products were<br />excluded.<br />In a clinical trial in which patients with a history of myocardial infarction were<br />treated with Simvastatin 80 mg/day (mean follow-up 6.7 years), the incidence of<br />myopathy was approximately 1.0% compared with 0.02% for patients on 20 mg/day.<br />Approximately half of these myopathy cases occurred during the first year of<br />treatment. The incidence of myopathy during each subsequent year of treatment<br />was approximately 0.1%. (See sections 4.8 and 5.1).<br />Creatine Kinase measurement<br />Creatine Kinase (CK) should not be measured following strenuous exercise or in the<br />presence of any plausible alternative cause of CK increase as this makes value<br />interpretation difficult. If CK levels are significantly elevated at baseline (&gt; 5 x ULN),<br />levels should be re-measured within 5 to 7 days later to confirm the results.<br />Before the treatment<br />All patients starting therapy with simvastatin, or whose dose of simvastatin is being<br />increased, should be advised of the risk of myopathy and told to report promptly any<br />unexplained muscle pain, tenderness or weakness.<br />Caution should be exercised in patients with pre-disposing factors for<br />rhabdomyolysis. In order to establish a reference baseline value, a CK level should be<br />measured before starting a treatment in the following situations:<br />&bull; Elderly (age 65 years)<br />- Female gender<br />&bull; Renal impairment<br />&bull; Uncontrolled hypothyroidism<br />&bull; Personal or familial history of hereditary muscular disorders<br />&bull; Previous history of muscular toxicity with a statin or fibrate<br />&bull; Alcohol abuse.<br />In such situations, the risk of treatment should be considered in relation to possible<br />benefit, and clinical monitoring is recommended. If a patient has previously<br />experienced a muscle disorder on a fibrate or a statin, treatment with a different<br />member of the class should only be initiated with caution. If CK levels are<br />significantly elevated at baseline (&gt; 5 x ULN), treatment should not be started.<br />Whilst on treatment<br />If muscle pain, weakness or cramps occur whilst a patient is receiving treatment with<br />a statin, their CK levels should be measured. If these levels are found, in the absence<br />of strenuous exercise, to be significantly elevated (&gt; 5 x ULN), treatment should be<br />stopped. If muscular symptoms are severe and cause daily discomfort, even if CK<br />levels are &lt; 5 x ULN, treatment discontinuation may be considered. If myopathy is<br />suspected for any other reason, treatment should be discontinued.<br />If symptoms resolve and CK levels return to normal, then re-introduction of the<br />statin or introduction of an alternative statin may be considered at the lowest dose<br />and with close monitoring.<br />A higher rate of myopathy has been observed in patients titrated to the 80mg dose<br />(see section 5.1). Periodic CK measurements are recommended as they may be<br />useful to identify subclinical cases of myopathy. However, there is no assurance that<br />such monitoring will prevent myopathy.<br />Therapy with simvastatin should be temporarily stopped a few days prior to elective<br />major surgery and when any major medical or surgical condition supervenes.<br />There have been rare reports of immune-mediated necrotizing myopathy (IMNM) an<br />autoimmune myopathy associated with (statin) use. IMNM is characterized by:<br />proximal muscle weakness and elevated serum creatine kinase which persist despite<br />discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy<br />without significant inflammation; improvement with immunosuppressive agents.<br />Measures to reduce the risk of myopathy caused by medicinal product interactions<br />(see also section 4.5)<br />The risk of myopathy and rhabdomyolysis is significantly increased by concomitant<br />use of simvastatin with potent inhibitors of CYP3A4 (such as itraconazole,<br />ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors,<br />nefazodone), as well as gemfibrozil, ciclosporin and danazol (see section 4.2).<br />The risk of myopathy and rhabdomyolysis is also increased by concomitant use of<br />other fibrates or by concomitant use of amiodarone or verapamil with higher doses<br />of simvastatin (see sections 4.2 and 4.5). The risk is increased by concomitant use of<br />diltiazem or amlopidine with simvastatin 80 mg (see sections 4.2 and 4.5).<br />The risk of myopathy including rhabdomyolysis may be increased by concomitant<br />administration of fusidic acid with statins (see section 4.5).<br />Consequently, regarding CYP3A4 inhibitors, the use of simvastatin concomitantly<br />with itraconazole, ketoconazole, HIV protease inhibitors, erythromycin,<br />clarithromycin, telithromycin and nefazodone is contraindicated (see sections 4.3<br />and 4.5). If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin<br />or telithromycin is unavoidable, therapy with simvastatin must be suspended during<br />the course of treatment. Moreover, caution should be exercised when combining<br />simvastatin with certain other less potent CYP3A4 inhibitors: ciclosporin, verapamil,<br />diltiazem (see sections 4.2 and 4.5). Concomitant intake of grapefruit juice and<br />simvastatin should be avoided.<br />The dose of simvastatin should not exceed 10 mg daily in patients receiving<br />concomitant medication with ciclosporin, danazol or gemfibrozil. The combined use<br />of simvastatin with gemfibrozil should be avoided, unless the benefits are likely to<br />outweigh the increased risks of this drug combination. The benefits of the combined<br />use of simvastatin 10 mg daily with other fibrates (except fenofibrate), ciclosporin or<br />danazol should be carefully weighed against the potential risks of these<br />combinations. (See sections 4.2 and 4.5.)<br />Caution should be used when prescribing fenofibrate with simvastatin, as either<br />agent can cause myopathy when given alone.<br />The combined use of simvastatin at doses higher than 20 mg daily with amiodarone<br />or verapamil should be avoided unless the clinical benefit is likely to outweigh the<br />increased risk of myopathy (see sections 4.2 and 4.5).<br />The combined use of simvastatin at doses higher than 40 mg daily with diltiazem or<br />amlopidine should be avoided unless the clinical benefit is likely to outweigh the<br />increased risk of myopathy (see sections 4.2 and 4.5).<br />Rare cases of myopathy/rhabdomyolysis have been associated with concomitant<br />administration of HMG-CoA reductase inhibitors and lipid modifying doses ( 1<br />g/day) of niacin (nicotinic acid), either of which can cause myopathy when given<br />alone.<br />Physicians contemplating combined therapy with simvastatin and lipid modifying<br />doses ( 1 g/day) of niacin (nicotinic acid) or products containing niacin should<br />carefully weigh the potential benefits and risks and should carefully monitor patients<br />for any signs and symptoms of muscle pain, tenderness, or weakness, particularly<br />during the initial months of therapy and when the dose of either medicinal product<br />is increased.<br />In an interim analysis of an ongoing clinical outcomes study, an independent safety<br />monitoring committee identified a higher than expected incidence of myopathy in<br />Chinese patients taking simvastatin 40 mg and nicotinic acid/laropiprant 2000 mg/40<br />mg. Therefore, caution should be used when treating Chinese patients with<br />simvastatin (particularly doses of 40 mg or higher) co administered with lipid<br />modifying doses ( 1 g/day) of niacin (nicotinic acid) or products containing niacin.<br />Because the risk of myopathy with statins is dose-related, the use of simvastatin 80<br />mg with lipid modifying doses ( 1 g/day) of niacin (nicotinic acid) or products<br />containing niacin is not recommended in Chinese patients. It is unknown whether<br />there is an increased risk of myopathy in other Asian patients treated with<br />simvastatin co-administered with lipid modifying doses ( 1 g/day) of niacin<br />(nicotinic acid) or products containing niacin.<br />If the combination proves necessary, patients on fusidic acid and simvastatin should<br />be closely monitored (see section 4.5). Temporary suspension of simvastain<br />treatment may be considered.<br />Hepatic effects<br />In clinical studies, persistent increases (to&gt; 3 x ULN) in serum transaminases have<br />occurred in a few adult patients who received simvastatin. When simvastatin was<br />interrupted or discontinued in these patients, the transaminase levels usually fell<br />slowly to pre-treatment levels.<br />It is recommended that liver function tests be performed before treatment begins<br />and thereafter when clinically indicated. Patients titrated to the 80-mg dose should<br />receive an additional test prior to titration, 3 months after titration to the 80-mg<br />dose, and periodically thereafter (e.g., semi-annually) for the first year of treatment.<br />Special attention should be paid to patients who develop elevated serum<br />transaminase levels, and in these patients, measurements should be repeated<br />promptly and then performed more frequently. If the transaminase levels show<br />evidence of progression, particularly if they rise to 3 x ULN and are persistent,<br />simvastatin should be discontinued.<br />The product should be used with caution in patients who consume substantial<br />quantities of alcohol.<br />As with other lipid-lowering agents, moderate (&lt; 3 x ULN) elevations of serum<br />transaminases have been reported following therapy with simvastatin. These<br />changes appeared soon after initiation of therapy with simvastatin, were often<br />transient, were not accompanied by any symptoms and interruption of treatment<br />was not required.<br />Interstitial lung disease<br />Exceptional cases of interstitial lung disease have been reported with some statins,<br />especially with long term therapy (see section 4.8). Presenting features can include<br />dyspnoea, non productive cough and deterioration in general health (fatigue, weight<br />loss and fever). If it is suspected a patient has developed interstitial lung disease,<br />statin therapy should be discontinued.<br />Use in children and adolescents (10-17 years of age)<br />Safety and effectiveness of simvastatin in patients 10-17 years of age with<br />heterozygous familial hypercholesterolaemia have been evaluated in a controlled<br />clinical trial in adolescent boys Tanner Stage II and above and in girls who were at<br />least one year post-menarche. Patients treated with simvastatin had an adverse<br />experience profile generally similar to that of patients treated with placebo. Doses<br />greater than 40 mg have not been studied in this population. In this limited<br />controlled study, there was no detectable effect on growth or sexual maturation in<br />the adolescent boys or girls, or any effect on menstrual cycle length in girls. (See<br />sections 4.2, 4.8, and 5.1.) Adolescent females should be counselled on appropriate<br />contraceptive methods while on simvastatin therapy (see sections 4.3 and 4.6). In<br />patients aged &lt; 18 years, efficacy and safety have not been studied for treatment<br />periods &gt; 48 weeks&#39; duration and long-term effects on physical, intellectual, and<br />sexual maturation are unknown. Simvastatin has not been studied in patients<br />younger than 10 years of age, nor in pre-pubertal children and pre-menarchal girls.<br />Excipient<br />This product contains lactose. Patients with rare hereditary problems of galactose<br />intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should<br />not take this medicine.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.<br />Pharmacodynamic interactions<br />Interactions with lipid-lowering medicinal products that can cause myopathy when<br />given alone. The risk of myopathy, including rhabdomyolysis, is increased during<br />concomitant administration with fibrates. Additionally, there is a pharmacokinetic<br />interaction with gemfibrozil resulting in increased simvastatin plasma levels (see<br />below Pharmacokinetic interactions and sections 4.2 and 4.4). When simvastatin and<br />fenofibrate are given concomitantly, there is no evidence that the risk of myopathy<br />exceeds the sum of the individual risks of each agent. Adequate pharmacovigilance<br />and pharmacokinetic data are not available for other fibrates. Rare cases of<br />myopathy/rhabdomyolysis have been associated with simvastatin co-administered<br />with lipid-modifying doses ( 1g/day) of niacin (see section 4.4).<br />Pharmacokinetic interactions<br />Prescribing recommendations for interacting agents are summarised in the table<br />below (further details are provided in the text; see also sections 4.2, 4.3 and 4.4).<br /><img src="data:image/png;base64,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" alt="" width="446" height="206" vspace="0" hspace="0" border="0" style="width:446px;height:206px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,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" alt="" width="446" height="234" vspace="0" hspace="0" border="0" style="width:446px;height:234px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Effects of other medicinal products on simvastatin<br />Interactions involving CYP3A4<br />Simvastatin is a substrate of cytochrome P450 3A4. Potent inhibitors of cytochrome<br />P450 3A4 increase the risk of myopathy and rhabdomyolysis by increasing the<br />concentration of HMG-CoA reductase inhibitory activity in plasma during simvastatin<br />therapy. Such inhibitors include itraconazole, ketoconazole, erythromycin,<br />clarithromycin, telithromycin, HIV protease inhibitors, and nefazodone. Concomitant<br />administration of itraconazole resulted in a more than 10-fold increase in exposure<br />to simvastatin acid (the active beta-hydroxyacid metabolite). Telithromycin caused<br />an 11-fold increase in exposure to simvastatin acid.<br />Therefore, combination with itraconazole, ketoconazole, HIV protease inhibitors,<br />erythromycin, clarithromycin, telithromycin and nefazodone is contraindicated. If<br />treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or<br />telithromycin is unavoidable, therapy with simvastatin must be suspended during<br />the course of treatment. Caution should be exercised when combining simvastatin<br />with certain other less potent CYP3A4 inhibitors: ciclosporin, verapamil, diltiazem<br />(see sections 4.2 and 4.4).<br />Ciclosporin<br />The risk of myopathy/rhabdomyolysis is increased by concomitant administration of<br />ciclosporin particularly with higher doses of simvastatin (see sections 4.2 and 4.4).<br />Therefore, the dose of simvastatin should not exceed 10 mg daily in patients<br />receiving concomitant medication with ciclosporin. Although the mechanism is not<br />fully understood, ciclosporin increases the AUC of simvastatin acid presumably due,<br />in part, to inhibition of CYP3A4.<br />Danazol<br />The risk of myopathy and rhabdomyolysis is increased by concomitant<br />administration of danazol with higher doses of simvastatin (see sections 4.2 and 4.4).<br />Gemfibrozil<br />Gemfibrozil increases the AUC of simvastatin acid by 1.9-fold, possibly due to<br />inhibition of the glucuronidation pathway (see sections 4.2 and 4.4).<br />Colchicine<br />There have been reports of myopathy and rhabdomyolysis with the concomitant<br />administration of colchicine and simvastatin in patients with renal insufficiency.<br />Close clinical monitoring of such patients taking this combination is advised<br />Amiodarone<br />The risk of myopathy and rhabdomyolysis is increased by concomitant<br />administration of amiodarone with higher doses of simvastatin (see section 4.4). In a<br />clinical trial, myopathy was reported in 6 % of patients receiving simvastatin 80 mg<br />and amiodarone. Therefore the dose of simvastatin should not exceed 20 mg daily in<br />patients receiving concomitant medication with amiodarone, unless the clinical<br />benefit is likely to outweigh the increased risk of myopathy and rhabdomyolysis.<br />Calcium Channel Blockers<br />&bull; Verapamil<br />The risk of myopathy and rhabdomyolysis is increased by concomitant<br />administration of verapamil with simvastatin 40 mg or 80 mg (see section 4.4). In a<br />pharmacokinetic study, concomitant administration with verapamil resulted in a 2.3<br />fold increase in exposure of simvastatin acid, presumably due, in part, to inhibition<br />of CYP3A4. Therefore, the dose of simvastatin should not exceed 20 mg daily in<br />patients receiving concomitant medication with verapamil, unless the clinical benefit<br />is likely to outweigh the increased risk of myopathy and rhabdomyolysis.<br />&bull; Diltiazem<br />The risk of myopathy and rhabdomyolysis is increased by concomitant<br />administration of diltiazem with simvastatin 80 mg (see section 4.4). The risk of<br />myopathy in patients taking simvastatin 40 mg was not increased by concomitant<br />diltiazem (see section 4.4). In a pharmacokinetic study, concomitant administration<br />of diltiazem caused a 2.7 fold increase in exposure of simvastatin acid, presumably<br />due to inhibition of CYP3A4. Therefore, the dose of simvastatin should not exceed 40<br />mg daily in patients receiving concomitant medication with diltiazem, unless the<br />clinical benefit is likely to outweigh the increased risk of myopathy and<br />rhabdomyolysis.<br />&bull; Amlodipine<br />Patients on amlodipine treated concomitantly with simvastatin 80 mg have a slightly<br />increased risk of myopathy. The risk of myopathy in patients taking simvastatin 40<br />mg was not increased by concomitant amlodipine. In a pharmacokinetic study,<br />concomitant administration of amlodipine caused a 1.6-fold increase in exposure of<br />simvastatin acid. Therefore, the dose of simvastatin should not exceed 40 mg daily in<br />patients receiving concomitant medication with amlopidine, unless the clinical<br />benefit is likely to outweigh the increased risk of myopathy and rhabdomyolysis.<br />Niacin (nicotinic acid)<br />Rare cases of myopathy/rhabdomyolysis have been associated with simvastatin co<br />administered with lipid modifying doses ( 1 g/day) of niacin (nicotinic acid). In a<br />pharmacokinetic study, the co administration of a single dose of nicotinic acid<br />prolonged-release 2 g with simvastatin 20 mg resulted in a modest increase in the<br />AUC of simvastatin and simvastatin acid and in the Cmax of simvastatin acid plasma<br />concentrations.<br />Fusidic acid<br />The risk of myopathy may be increased by concomitant administration of fusidic acid<br />with statins, including simvastatin. Isolated cases of rhabdomyolysis have been<br />reported with simvastatin. Temporary suspension of simvastatin treatment may be<br />considered. If it proves necessary, patients on fusidic acid and simvastatin should be<br />closely monitored (see section 4.4).<br />Grapefruit juice<br />Grapefruit juice inhibits cytochrome P450 3A4. Concomitant intake of large<br />quantities (over 1 litre daily) of grapefruit juice and simvastatin resulted in a 7-fold<br />increase in exposure to simvastatin acid. Intake of 240 ml of grapefruit juice in the<br />morning and simvastatin in the evening also resulted in a 1.9-fold increase. Intake of<br />grapefruit juice during treatment with simvastatin should therefore be avoided.<br />Effects of simvastatin on the pharmacokinetics of other medicinal products.<br />Simvastatin does not have an inhibitory effect on cytochrome P450 3A4. Therefore,<br />simvastatin is not expected to affect plasma concentrations of substances<br />metabolised via cytochrome P450 3A4.<br />Oral anticoagulants<br />In two clinical studies, one in normal volunteers and the other in<br />hypercholesterolaemic patients, simvastatin 20-40 mg/day modestly potentiated the<br />effect of coumarin anticoagulants: the prothrombin time, reported as International<br />Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in<br />the volunteer and patient studies, respectively. Very rare cases of elevated INR have<br />been reported. In patients taking coumarin anticoagulants, prothrombin time should<br />be determined before starting simvastatin and frequently enough during early<br />therapy to ensure that no significant alteration of prothrombin time occurs. Once a<br />stable prothrombin time has been documented, prothrombin times can be<br />monitored at the intervals usually recommended for patients on coumarin<br />anticoagulants. If the dose of simvastatin is changed or discontinued, the same<br />procedure should be repeated. Simvastatin therapy has not been associated with<br />bleeding or with changes in prothrombin time in patients not taking anticoagulants.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy: Simvastatin is contraindicated during pregnancy (see section 4.3).<br />Safety in pregnant women has not been established. No controlled clinical trials with<br />simvastatin have been conducted in pregnant women. Rare reports of congenital<br />anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have<br />been received. However, in an analysis of approximately 200 prospectively followed<br />pregnancies exposed during the first trimester to Simvastatin or another closely<br />related HMG-CoA reductase inhibitor, the incidence of congenital anomalies was<br />comparable to that seen in the general population. This number of pregnancies was<br />statistically sufficient to exclude a 2.5-fold or greater increase in congenital<br />anomalies over the background incidence.<br />Although there is no evidence that the incidence of congenital anomalies in offspring<br />of patients taking Simvastatin or another closely related HMG-CoA reductase<br />inhibitor differs from that observed in the general population, maternal treatment<br />with Simvastatin may reduce the foetal levels of mevalonate which is a precursor of<br />cholesterol biosynthesis. Atherosclerosis is a chronic process, and ordinarily<br />discontinuation of lipid-lowering medicinal products during pregnancy should have<br />little impact on the long-term risk associated with primary hypercholesterolaemia.<br />For these reasons, Simvastatin must not be used in women who are pregnant, trying<br />to become pregnant or suspect they are pregnant.<br />Treatment with Simvastatin must be suspended for the duration of pregnancy or<br />until it has been determined that the woman is not pregnant. (See section 4.3.)<br />Breastfeeding : It is not known whether simvastatin or its metabolites are excreted<br />in human milk. Because many medicinal products are excreted in human milk and<br />because of the potential for serious adverse reactions, women taking Simvastatin<br />must not breast-feed their infants (see section 4.3).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Simvastatin has no or negligible influence on the ability to drive and use machines.<br />However, when driving vehicles or operating machines, it should be taken into<br />account that dizziness has been reported rarely in post-marketing experiences.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The frequencies of the following adverse events, which have been reported during<br />clinical studies and/or post-marketing use, are categorized based on an assessment<br />of their incidence rates in large, long-term, placebo-controlled, clinical trials<br />including HPS and 4S with 20,536 and 4,444 patients, respectively (see section 5.1).<br />For HPS, only serious adverse events were recorded as well as myalgia, increases in<br />serum transaminases and CK. For 4S, all the adverse events listed below were<br />recorded. If the incidence rates on simvastatin were less than or similar to that of<br />placebo in these trials, and there were similar reasonably causally related<br />spontaneous report events, these adverse events are categorized as &ldquo;rare&rdquo;.<br />In HPS (see section 5.1) involving 20,536 patients treated with 40 mg/day of<br />Simvastatin (n = 10,269) or placebo (n = 10,267), the safety profiles were comparable<br />between patients treated with Simvastatin 40 mg and patients treated with placebo<br />over the mean 5 years of the study. Discontinuation rates due to side effects were<br />comparable (4.8 % in patients treated with Simvastatin 40 mg compared with 5.1 %<br />in patients treated with placebo). The incidence of myopathy was &lt; 0.1 % in patients<br />treated with Simvastatin 40 mg. Elevated transaminases (&gt; 3 x ULN confirmed by<br />repeat test) occurred in 0.21 % (n = 21) of patients treated with Simvastatin 40 mg<br />compared with 0.09 % (n = 9) of patients treated with placebo.<br />The frequencies of adverse events are ranked according to the following: Very<br />common&gt; 1/10), Common ( 1/100, &lt; 1/10), Uncommon ( 1/1000, &lt; 1/100), Rare (<br />1/10,000, &lt; 1/1000), Very Rare (&lt; 1/10,000), not known (cannot be estimated<br />from the available data).<br />Investigations:<br />Rare:<br /> increases in serum transaminases (alanine aminotransferase, aspartate<br />aminotransferase, &gamma;-glutamyl transpeptidase) (see section 4.4 Hepatic effects),<br />elevated alkaline phosphatase; increase in serum CK levels (see section 4.4).<br /> Increases in glycosylated hemoglobin (HbA1c) and fasting serum glucose levels<br />have been reported with statin use.<br />Blood and lymphatic system disorders:<br />Rare: anaemia<br />Nervous system disorders:<br />Rare: headache, paresthesia, dizziness, peripheral neuropathy<br />Very rare: the potential for generally non-serious and reversible cognitive side effects<br />(memory loss, confusion, etc.)<br />Gastrointestinal disorders:<br />Rare: constipation, abdominal pain, flatulence, dyspepsia, diarrhoea, nausea,<br />vomiting, pancreatitis<br />Hepato-biliary disorders:<br />Rare: hepatitis/jaundice<br />Very rare: fatal and non-fatal hepatic failure<br />Skin and subcutaneous tissue disorders:<br />Rare: rash, pruritus, alopecia<br />Musculoskeletal, connective tissue and bone disorders:<br />Rare: myopathy*, rhabdomyolysis (see section 4.4), myalgia, muscle cramps<br />*In a clinical trial, myopathy occurred commonly in patients treated with<br />Simvastatin 80 mg/day compared to patients treated with 20 mg/day (1.0% vs<br />0.02%, respectively).<br />General disorders and administration site conditions:<br />Rare: asthenia<br />An apparent hypersensitivity syndrome has been reported rarely which has included<br />some of the following features: angioedema, lupus-like syndrome, polymyalgia<br />rheumatica, dermatomyositis, vasculitis, thrombocytopenia, eosinophilia, ESR<br />increased, arthritis and arthralgia, urticaria, photosensitivity, fever, flushing,<br />dyspnoea and malaise.<br />Psychiatric disorders:<br />Very rare: insomnia<br />The following adverse events have been reported with some statins:<br />&bull; Sleep disturbances, including insomnia and nightmares<br />&bull; Sexual dysfunction<br />&bull; Depression<br />&bull; Exceptional cases of interstitial lung disease, especially with long term therapy (see<br />section 4.4)<br />Children and adolescents (10-17 years of age)<br />In a 48-week study involving children and adolescents (boys Tanner Stage II and<br />above and girls who were at least one year post-menarche) 10-17 years of age with<br />heterozygous familial hypercholesterolaemia (n = 175), the safety and tolerability<br />profile of the group treated with simvastatin was generally similar to that of the<br />group treated with placebo. The long-term effects on physical, intellectual, and<br />sexual maturation are unknown. No sufficient data are currently available after one<br />year of treatment. (See sections 4.2, 4.4, and 5.1.)<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To date, a few cases of overdosage have been reported; the maximum dose taken<br />was 3.6 g. All patients recovered without sequelae. There is no specific treatment in<br />the event of overdose. In this case, symptomatic and supportive measures should be<br />adopted.<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: HMG-CoA reductase inhibitor<br />ATC-Code: C10A A01<br />After oral ingestion, simvastatin, which is an inactive lactone, is hydrolyzed in the<br />liver to the corresponding active beta-hydroxyacid form which has a potent activity<br />in inhibiting HMG-CoA reductase (3 hydroxy &ndash; 3 methylglutaryl CoA reductase). This<br />enzyme catalyses the conversion of HMG-CoA to mevalonate, an early and ratelimiting step in the biosynthesis of cholesterol.<br />Simvastatin has been shown to reduce both normal and elevated LDL-C<br />concentrations. LDL is formed from very-low-density protein (VLDL) and is<br />catabolised predominantly by the high affinity LDL receptor. The mechanism of the<br />LDL-lowering effect of Simvastatin may involve both reduction of VLDL cholesterol<br />(VLDL-C) concentration and induction of the LDL receptor, leading to reduced<br />production and increased catabolism of LDL-C. Apolipoprotein B also falls<br />substantially during treatment with Simvastatin. In addition, Simvastatin moderately<br />increases HDL-C and reduces plasma TG. As a result of these changes the ratios of<br />total- to HDL-C and LDL- to HDL-C are reduced.<br />High Risk of Coronary Heart Disease (CHD) or Existing Coronary Heart Disease<br />In the Heart Protection Study (HPS), the effects of therapy with Simvastatin were<br />assessed in 20,536 patients (age 40-80 years), with or without hyperlipidaemia, and<br />with coronary heart disease, other occlusive arterial disease or diabetes mellitus. In<br />this study, 10,269 patients were treated with Simvastatin 40 mg/day and 10,267<br />patients were treated with placebo for a mean duration of 5 years. At baseline, 6,793<br />patients (33 %) had LDL-C levels below 116 mg/dL; 5,063 patients (25 %) had levels<br />between 116 mg/dL and 135 mg/dL; and 8,680 patients (42 %) had levels greater<br />than 135 mg/dL.<br />Treatment with Simvastatin 40 mg/day compared with placebo significantly reduced<br />the risk of all cause mortality (1328 [12.9 %] for simvastatin-treated patients versus<br />1507 [14.7 %] for patients given placebo; p = 0.0003), due to an 18 % reduction in<br />coronary death rate (587 [5.7 %] versus 707 [6.9 %]; p = 0.0005; absolute risk<br />reduction of 1.2 %). The reduction in non-vascular deaths did not reach statistical<br />significance. Simvastatin also decreased the risk of major coronary events (a<br />composite endpoint comprised of non-fatal MI or CHD death) by 27 % (p &lt; 0.0001).<br />Simvastatin reduced the need for undergoing coronary revascularization procedures<br />(including coronary artery bypass grafting or percutaneous transluminal coronary<br />angioplasty) and peripheral and other noncoronary revascularization procedures by<br />30 % (p &lt; 0.0001) and 16 % (p = 0.006), respectively. Simvastatin reduced the risk of<br />stroke by 25 % (p &lt; 0.0001), attributable to a 30 % reduction in ischemic stroke (p &lt;<br />0.0001). In addition, within the subgroup of patients with diabetes, Simvastatin<br />reduced the risk of developing macrovascular complications, including peripheral<br />revascularization procedures (surgery or angioplasty), lower limb amputations, or leg<br />ulcers by 21 % (p = 0.0293). The proportional reduction in event rate was similar in<br />each subgroup of patients studied, including those without coronary disease but<br />who had cerebrovascular or peripheral artery disease, men and women, those aged<br />either under or over 70 years at entry into the study, presence or absence of<br />hypertension, and notably those with LDL cholesterol below 3.0 mmol/l at inclusion.<br />In the Scandinavian Simvastatin Survival Study (4S), the effect of therapy with<br />Simvastatin on total mortality was assessed in 4,444 patients with CHD and baseline<br />total cholesterol 212-309 mg/dL (5.5-8.0 mmol/L). In this multicenter, randomised,<br />double-blind, placebo-controlled study, patients with angina or a previous<br />myocardial infarction (MI) were treated with diet, standard care, and either<br />Simvastatin 20-40 mg/day (n = 2,221) or placebo (n = 2,223) for a median duration of<br />5.4 years. Simvastatin reduced the risk of death by 30 % (absolute risk reduction of<br />3.3 %). The risk of CHD death was reduced by 42 % (absolute risk reduction of 3.5 %).<br />Simvastatin also decreased the risk of having major coronary events (CHD death plus<br />hospital-verified and silent nonfatal MI) by 34 %. Furthermore, Simvastatin<br />significantly reduced the risk of fatal plus nonfatal cerebrovascular events (stroke<br />and transient ischemic attacks) by 28 %. There was no statistically significant<br />difference between groups in non-cardiovascular mortality.<br />The Study of the Effectiveness of Additional Reductions in Cholesterol and<br />Homocysteine (SEARCH) evaluated the effect of treatment with Simvastatin 80 mg<br />versus 20 mg (median follow-up 6.7 yrs) on major vascular events (MVEs; defined as<br />fatal CHD, non-fatal MI, coronary revascularization procedure, non-fatal or fatal<br />stroke, or peripheral revascularization procedure) in 12,064 patients with a history of<br />myocardial infarction. There was no significant difference in the incidence of MVEs<br />between the 2 groups Simvastatin 20 mg (n = 1553; 25.7 %) vs. Simvastatin 80 mg (n<br />= 1477; 24.5 %); RR 0.94, 95 % CI: 0.88 to 1.01. The absolute difference in LDL-C<br />between the two groups over the course of the study was 0.35 &plusmn; 0.01 mmol/L. The<br />safety profiles were similar between the two treatment groups except that the<br />incidence of myopathy was approximately 1.0 % for patients on Simvastatin 80 mg<br />compared with 0.02 % for patients on 20 mg. Approximately half of these myopathy<br />cases occurred during the first year of treatment. The incidence of myopathy during<br />each subsequent year of treatment was approximately 0.1 %.<br />Primary Hypercholesterolaemia and Combined Hyperlipidaemia<br />In studies comparing the efficacy and safety of simvastatin 10, 20, 40 and 80 mg daily<br />in patients with hypercholesterolemia, the mean reductions of LDL-C were 30, 38, 41<br />and 47 %, respectively. In studies of patients with combined (mixed) hyperlipidaemia<br />on simvastatin 40 mg and 80 mg, the median reductions in triglycerides were 28 and<br />33 % (placebo: 2 %), respectively, and mean increases in HDL-C were 13 and 16 %<br />(placebo: 3 %), respectively.<br />Clinical Studies in Children and Adolescents (10-17 years of age)<br />In a double-blind, placebo-controlled study, 175 patients (99 boys Tanner Stage II<br />and above and 76 girls who were at least one year post-menarche) 10-17 years of<br />age (mean age 14.1 years) with heterozygous familial hypercholesterolaemia (heFH)<br />were randomized to simvastatin or placebo for 24 weeks (base study). Inclusion in<br />the study required a baseline LDL-C level between 160 and 400 mg/dL and at least<br />one parent with an LDL-C level &gt; 189 mg/dL. The dosage of simvastatin (once daily in<br />the evening) was 10 mg for the first 8 weeks, 20 mg for the second 8 weeks, and 40<br />mg thereafter. In a 24-week extension, 144 patients elected to continue therapy and<br />received simvastatin 40 mg or placebo.<br />Simvastatin significantly decreased plasma levels of LDL-C, TG, and Apo B. Results<br />from the extension at 48 weeks were comparable to those observed in the base<br />study.<br />After 24 weeks of treatment, the mean achieved LDL-C value was 124.9 mg/dL<br />(range: 64.0- 289.0 mg/dL) in the simvastatin 40 mg group compared to 207.8 mg/dL<br />(range: 128.0-334.0 mg/dL) in the placebo group.<br />After 24 weeks of simvastatin treatment (with dosages increasing from 10, 20 and up<br />to 40 mg daily at 8- week intervals), simvastatin decreased the mean LDL-C by 36.8 %<br />(placebo: 1.1 % increase from baseline), Apo B by 32.4 % (placebo: 0.5 %), and<br />median TG levels by 7.9 % (placebo: 3.2 %) and increased mean HDL-C levels by 8.3<br />% (placebo: 3.6 %). The long-term benefits of simvastatin on cardiovascular events in<br />children with heFH are unknown.<br />The safety and efficacy of doses above 40 mg daily have not been studied in children<br />with heterozygous familial hypercholesterolaemia. The long-term efficacy of<br />simvastatin therapy in childhood to reduce morbidity and mortality in adulthood has<br />not been established.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Simvastatin is an inactive lactone which is readily hydrolyzed in vivo to the<br />corresponding beta-hydroxyacid, a potent inhibitor of HMG-CoA reductase.<br />Hydrolysis takes place mainly in the liver; the rate of hydrolysis in human plasma is<br />very slow.<br />The pharmacokinetic properties have been evaluated in adults. Pharmacokinetic<br />data in children and adolescents are not available.<br />Absorption<br />In man simvastatin is well absorbed and undergoes extensive hepatic first-pass<br />extraction. The extraction in the liver is dependent on the hepatic blood flow. The<br />liver is the primary site of action of the active form. The availability of the<br />betahydroxyacid to the systemic circulation following an oral dose of simvastatin<br />was found to be less than 5 % of the dose. Maximum plasma concentration of active<br />inhibitors is reached approximately 1-2 hours after administration of simvastatin.<br />Concomitant food intake does not affect the absorption. The pharmacokinetics of<br />single and multiple doses of simvastatin showed that no accumulation of medicinal<br />product occurred after multiple dosing.<br />Distribution<br />The protein binding of simvastatin and its active metabolite is&gt; 95 %.<br />Elimination<br />Simvastatin is a substrate of CYP3A4 (see sections 4.3 and 4.5). The major<br />metabolites of simvastatin present in human plasma are the beta-hydroxyacid and<br />four additional active metabolites. Following an oral dose of radioactive simvastatin<br />to man, 13 % of the radioactivity was excreted in the urine and 60 % in the faeces<br />within 96 hours. The amount recovered in the faeces represents absorbed medicinal<br />product equivalents excreted in bile as well as unabsorbed medicinal product.<br />Following an intravenous injection of the beta-hydroxyacid metabolite, its half-life<br />averaged 1.9 hours. An average of only 0.3 % of the IV dose was excreted in urine as<br />inhibitors.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on conventional animal studies regarding pharmacodynamics, repeated dose<br />toxicity, genotoxicity and carcinogenicity, there are no other risks for the patient<br />than may be expected on account of the pharmacological mechanism. At maximally<br />tolerated doses in both the rat and the rabbit, simvastatin produced no foetal<br />malformations, and had no effects on fertility, reproductive function or neonatal<br />development.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>List of Excipients:<br />Lactose, Butylate Hydroxy Anisole, Hydroxypropylcellulose (HPC-L, HPC-LH22), Magnesium<br />stearate, Opadry Pink.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />Store in the original package<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>How supplied<br />PVC-PVDC/Aluminum blister pack<br />SIMVATEN&reg; 10mg is available in packs of 30 tablets.<br />SIMVATEN&reg; 20mg is available in packs of 30 tablets.<br />SIMVATEN&reg; 40mg is available in packs of 30 tablets.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited
Jeddah – Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sep. 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>